Re: Zenith trial partners
in response to
by
posted on
Feb 02, 2023 02:15AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
KBC - I was never saying that money would or should be directed toward RVX, only stating the only way it could legally. If it was a good investment so in the shareholders interest and Zenith had looked after its shareholders and still had cash to do it, that is the only way it could happen. That isn't how things are and I don't expect to be.